As of November, 2026, a multi-cancer early detection test can find some cancers that no routine screening looks for, but it is still an optional add-on, not a replacement for standard screening. Two large studies published in September 2026 show the Galleri test finds real cancers with relatively few false alarms. However, the biggest randomized trial did not show the drop in late-stage cancers it was designed to prove.
If you are 50 or older, are already up to date on mammograms, colon cancer screening and other recommended tests, and can comfortably spend $689 to $949 a year, a multi-cancer test is a reasonable option to discuss with your doctor. On a tight budget, your money goes further on the screenings with proven benefit, most of which insurance covers at no cost to you.
Below, we cover what these blood tests do, what the newest research found, how often to test, what each test costs and how to order one. For the wider picture of preventive testing, start with our guide to setting your health baseline.
What is a multi-cancer early detection test?
A multi-cancer early detection (MCED) test is a blood test that looks for traces of tumor DNA, and sometimes tumor proteins, circulating in your bloodstream. A positive result means the test found a cancer signal, and it usually predicts where in the body the signal came from. It is a screening test, not a diagnosis: imaging or a biopsy must confirm any cancer.
The appeal is the size of the gap MCED tests aim to fill. In the United States, only 14% of cancers are found through guideline-recommended screening, and more than 70% of cancer deaths come from cancers with no recommended screening test at all, according to the authors of the PATHFINDER 2 study in Nature Medicine. Pancreatic, ovarian, liver and stomach cancers, for example, usually announce themselves only through symptoms.
Three MCED tests matter for US readers right now:
- Galleri from GRAIL reads chemical tags (methylation patterns) on DNA fragments in the blood and screens for more than 50 cancer types. It has the largest body of published evidence.
- Cancerguard from Exact Sciences, which Abbott acquired in March 2026, combines DNA changes with tumor-associated protein levels and also targets more than 50 cancer types.
- Shield MCD from Guardant Health is an optional multi-cancer report added to Guardant’s Shield colon cancer blood test, covering 10 cancer types.
None of the three has US Food and Drug Administration (FDA) approval for multi-cancer screening yet. All are sold as laboratory-developed tests, which labs can offer without FDA approval.
What the 2026 Galleri research shows
The two largest studies of any multi-cancer early detection test came out on the same day, September 22, 2026, and both evaluated Galleri. Together they show the test is usually right when it flags cancer, but it misses most cancers, and its effect on late-stage disease is not yet proven. GRAIL funded and helped run both studies, so independent confirmation still matters.
PATHFINDER 2: few false alarms, many missed cancers
The PATHFINDER 2 study gave one Galleri test to 35,878 adults aged 50 and older at 32 sites in the United States and Canada, then tracked them for a year. Among the 32,007 people with complete follow-up, the results looked like this:
- Positive results were rare. Only 0.9% of people got a cancer signal, and 60.3% of those turned out to have cancer.
- False alarms were uncommon. Specificity was 99.64%, meaning about 1 in 280 people without cancer got a false positive.
- The location guess was good. The test pointed to the right organ for 91.3% of the cancers it found.
- Many finds were early. Of new cancers it caught, 53.0% were stage I or II, and 72.8% of all its finds were cancer types with no standard screening test.
The weak spot is sensitivity. During the year, doctors diagnosed 440 cancers in this group, and Galleri had flagged 173 of them, missing roughly six in ten. Sensitivity was 39.3% across all cancers but 69.8% for 12 especially deadly types, such as pancreatic, liver and lung cancer. Many of the misses were early breast and prostate cancers, which existing screening tests already target.
On safety, 0.6% of all participants had an invasive procedure such as a biopsy or endoscopy after a positive result, and 90.5% of those procedures were nonsurgical. People with cancer got a diagnosis in a median of 37 days, while those without cancer waited a median of 70 days to be cleared. Because the study had no comparison group, the authors themselves say randomized trials with longer follow-up must establish whether testing actually helps people.
NHS-Galleri: the randomized trial missed its main goal
The NHS-Galleri trial, published in The New England Journal of Medicine, randomly split 142,250 adults aged 50 to 77 in England into two groups. One group had Galleri testing once a year for three years on top of usual care; the other group gave blood that was stored but not tested.
The trial’s main question was whether testing would reduce stage III and IV cancers across 12 deadly cancer types. It did not: 706 people in the tested group and 688 in the control group developed those late-stage cancers, a rate ratio of 1.03 (95% confidence interval 0.92 to 1.14), which is no meaningful difference.
The details are more encouraging than the headline. Stage IV cancers fell (341 versus 394 people), and by the third annual round, the tested group’s stage IV rate was 26% lower. Even so, stage III cancers rose by a similar amount (360 versus 287), which cancelled out the gain. Diagnoses made in emergency settings, which carry worse survival, dropped 21.3% (225 versus 286).
Across the three rounds, 1,801 tests came back positive, and 52% of those people had cancer. No serious adverse events were linked to testing. The trial was not built to measure deaths from cancer; the investigators plan those analyses at three and six years after the final visit. They also note they cannot yet tell whether the extra early-stage cancers found reflect real early detection or overdiagnosis, meaning cancers that would never have caused harm.
An accompanying Nature Medicine commentary summed up the state of play: the studies answer questions about performance and safety, and the next challenge is proving a benefit across whole populations. A companion analysis of test performance in NHS-Galleri appeared in the same issue.
What a Galleri result means for 1,000 people tested
For every 1,000 adults aged 50 and older who take one Galleri test, about 9 get a positive result, roughly 5 of whom have cancer. Meanwhile, about 8 more people in that group will be diagnosed with a cancer the test missed within the year. These figures come straight from the PATHFINDER 2 results, scaled to 1,000 people.
| Outcome after one test | People per 1,000 tested | What happens next |
|---|---|---|
| Positive, cancer confirmed | 5.4 | Imaging and biopsy guided by the predicted organ; diagnosis in a median of 37 days |
| Positive, no cancer found | 3.6 | Workup, often imaging; a median of 70 days to be cleared |
| Negative, but cancer diagnosed within a year | 8.3 | Found by standard screening or symptoms; many were breast or prostate cancers |
| Negative, no cancer within a year | 982.7 | Nothing, other than continuing routine screening |
The practical lesson cuts both ways. A positive result deserves prompt follow-up, since six in ten turn out to be cancer. A negative result, however, should never talk you out of a mammogram, colonoscopy, low-dose lung scan or a doctor’s visit for new symptoms.
Is a multi-cancer early detection test worth it?
Multi-cancer early detection tests are worth considering as an extra layer for some people, but no study has yet shown that they help people live longer. No major guideline group, including the U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society, recommends them for routine screening, as a 2025 peer-reviewed review for clinicians notes. In our view, the 2026 data make them a defensible personal choice, not a public health recommendation.
The case for testing rests on what PATHFINDER 2 and NHS-Galleri showed: the test finds cancers that nothing else screens for, often at stage I or II, with few false alarms. What they did not show matters just as much. Neither study proves that finding these cancers earlier prevents deaths, and the extra stage III cancers in NHS-Galleri leave room for overdiagnosis. Beyond that, the test misses about six in ten cancers diagnosed within a year, so it cannot replace anything you already do.
Who might reasonably consider one
- Adults 50 and older, since cancer risk climbs with age and nearly all of the published data come from this group.
- Former or current smokers, and people with a past cancer, whose risk is higher. In NHS-Galleri’s exploratory subgroup analyses, people with a prior cancer and men showed some of the largest differences, though the trial was not powered to prove benefit in any subgroup.
- People already current on standard screening who want coverage for cancers like pancreatic, liver and ovarian cancer, and who can afford the cost without trading off proven care.
Who should probably wait
- People under 50, because little performance data exist for this age group.
- Anyone behind on recommended screening. A colonoscopy or mammogram has decades of evidence behind it; spend there first, and see our guide to colon cancer screening options.
- People who would struggle with the cost of a follow-up workup or with the anxiety of a false positive. In PATHFINDER 2, participant-reported anxiety rose temporarily for people whose positive result was confirmed as cancer, then returned to baseline within a year.
Whatever you decide, make the call with your primary care provider (PCP), who can weigh your personal and family history. If you need a doctor like that, our article on building your personal health team is a good place to start.
How often should you get a multi-cancer early detection test?
If you test at all, plan on once a year. GRAIL markets Galleri as a yearly test, Exact Sciences says Cancerguard can be considered annually, and NHS-Galleri tested people every 12 months for three years.
That said, no study has compared intervals, and the NHS-Galleri investigators state their trial was not designed to test different screening schedules. One detail hints that repeat testing matters: the gap in stage IV cancers between the two groups widened from the first round to the third, though those round-by-round figures are exploratory.
The arithmetic matters too. At list price, ten years of annual Galleri testing costs $9,490, before any follow-up imaging. A single test is a much smaller commitment, but it gives you a snapshot, not ongoing screening.
How much does the Galleri multi-cancer early detection test cost?
The Galleri test has a list price of $949, and Cancerguard costs $689 self-pay. Most health insurance plans do not cover either test, so expect to pay out of pocket unless your employer offers one as a benefit.
| Test | Maker | Self-pay price | Who it is for | How to get it |
|---|---|---|---|---|
| Galleri | GRAIL | $949 list; blood draw included with a GRAIL partner | Adults 50+ or at elevated risk | Your doctor, or online via an independent telehealth provider |
| Cancerguard | Exact Sciences (Abbott) | $689 | Adults 50 to 84 with no cancer in the past 3 years | Your doctor, or online via telehealth |
| Shield MCD | Guardant Health | No separate US price published | Adults having a Shield colon cancer blood test | Your doctor opts in when ordering Shield |
Discounts shift often. GRAIL is currently offering $250 off Galleri orders placed between October 3 and December 31, 2026, and telehealth company Hims & Hers sells Galleri at $250 below list as an add-on to its lab plans. Some employers, unions and insurers also offer Galleri free or discounted to members.
The test itself may not be your biggest bill. A positive result typically leads to imaging such as a computed tomography (CT) or positron emission tomography (PET) scan, and possibly a biopsy, and your insurer decides whether to cover that workup. Exact Sciences runs an imaging reimbursement program toward non-covered imaging for eligible Cancerguard patients who apply. Ask about follow-up costs before you order any of these tests.
Can you order a Galleri test yourself?
Yes, though not without a prescription. Galleri and Cancerguard both require a clinician’s order, but each company lets you request the test online, where an independent telehealth doctor reviews your health questionnaire and approves it if appropriate. For Galleri, that provider is Recuro Health.
How to get a multi-cancer early detection test
- Talk to your primary care provider first; GRAIL offers a discussion guide and order form for your doctor.
- Or request the test online at galleri.com or cancerguard.com and complete the health questionnaire.
- Pay the self-pay price, applying any employer or promotional discount.
- Give a blood sample at a partner lab or through an at-home draw; no fasting is required for Galleri.
- Review results with the ordering clinician, and if a cancer signal is detected, start the recommended follow-up promptly.
The ordering route matters more than it seems. If a telehealth doctor you have never met orders the test, make sure your own physician will handle a positive result, since the workup runs through your regular care and insurance. Shield MCD is different: you cannot request it on its own, because it is available only when a physician opts in while ordering Guardant’s Shield colon cancer test.
Free and lower-cost ways to get tested
The cheapest route to a multi-cancer test is often a research study. Two are enrolling in the United States now:
- The REACH study, for people on Medicare. GRAIL’s REACH/Galleri-Medicare study enrolls people 50 and older with traditional Medicare or Medicare Advantage who have not had a Galleri test, offering up to three annual tests. Medicare covers the test for study participants, and the study plans to enroll about 50,000 people.
- The Vanguard Study, for adults 45 to 75. The National Cancer Institute (NCI) is running the Vanguard Study to prepare for a larger randomized trial. It aims to enroll up to 24,000 people, who are randomly assigned to one of two multi-cancer tests or to a control group, so you may not receive a test.
Beyond studies, check your benefits. A number of employers and union health funds now offer Galleri at no cost or at a discount, and some telehealth platforms bundle it with lab memberships.
Above all, use the free screenings first. Under the Affordable Care Act (ACA), most private plans must cover USPSTF-recommended screenings for breast, cervical, colorectal and lung cancer without cost-sharing. Those tests have the strongest evidence of any cancer screening available today.
FDA approval and Medicare coverage: what comes next
Galleri could become the first FDA-approved multi-cancer screening test within months, and Medicare coverage could follow as early as 2028. As of early November 2026, the FDA had not yet issued its decision.
GRAIL submitted its premarket approval (PMA) application on January 29, 2026. On September 23, an FDA advisory panel voted 7 to 2, with one abstention, that Galleri’s benefits outweigh its risks for adults 50 and older. Panelists backed its safety unanimously but split 6 to 4 on whether it is effective. The FDA usually follows its advisers but is not bound to.
Congress has already cleared the payment path. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, signed into law on February 3, 2026, lets Medicare cover FDA-approved multi-cancer screening tests beginning in 2028. Medicare must still set the coverage details, and private insurers generally are not required to cover a screening test until the USPSTF recommends it.
For readers deciding today, these milestones change cost and access more than the science. FDA approval would confirm the test performs as labeled; it would not by itself show that testing saves lives.
Frequently asked questions
Is the Galleri test accurate?
Galleri is accurate when it flags cancer but misses many cancers. In PATHFINDER 2, 60.3% of positive results were confirmed as cancer and only 0.36% of people without cancer got a false positive. However, the test detected just 39.3% of all cancers diagnosed within a year, so a negative result does not rule cancer out.
Is Galleri covered by insurance or Medicare?
Most insurance plans do not cover Galleri today, and Medicare does not cover it outside the REACH research study. A 2026 federal law allows Medicare to cover FDA-approved multi-cancer screening tests starting in 2028, but Galleri still awaits an FDA decision. Some employers and union health plans offer it as a benefit.
Can Galleri replace a colonoscopy or mammogram?
No. Galleri is meant to be used alongside standard screening, not instead of it. In PATHFINDER 2, many cancers the test missed were early breast and prostate cancers that routine screening is designed to catch. Keep up with every screening your doctor recommends, whatever a multi-cancer test shows.
What happens if my Galleri test is positive?
A positive result means the test found a cancer signal and predicted its likely origin, such as the colon or pancreas. Your doctor then orders targeted imaging, blood work or a biopsy to confirm or rule out cancer. In PATHFINDER 2, about six in ten people with a positive result were diagnosed with cancer.
